Background: Cancer patients have a higher risk for thrombosis that is usually related to advanced stage and poor prognosis. This study aimed to identify the clinical picture and outcome of non-small cell lung cancer ( NSCLC) and small cell lung cancer (SCLC) patients with pulmonary embolism (PE). Patients and Methods: From 1996 to 2005, the clinical presentation of lung cancer patients with PE was evaluated. Their survival was compared with matched controls by log-rank test. Results: A total of 24 patients, 17 men ( 70.8%) and 7 women (median age: 62.5 years), were identified . Nineteen patients (79.2%) initially presented with advanced lung cancer ( 16 stage IV, 1 stage III-b NSCLC and 2 extensive-stage SCLC). Wells' clinical prediction sc...
Background Current guidelines suggest treating cancer patients with incidental pulmonary embolism (P...
PURPOSE Pulmonary embolism is incidentally diagnosed in up to 5% of patients with cancer on routine ...
Venous thromboembolism (VTE) is the leading cause of mortality and morbidity in patients with cancer...
Background and objective Malignant tumors are often complicated with pulmonary thromboembolism (PTE)...
BACKGROUND:Pulmonary embolism (PE) is correlated with increased mortality among patients with lung c...
Background: In patients with lung cancer and venous thromboembolism (VTE), the influence of cancer h...
Background: In patients with lung cancer and venous thromboembolism (VTE), the influence of cancer h...
In cancer patients, pulmonary embolism (PE) is the second leading cause of death after the cancer it...
Background and objective Malignant tumors often combined with venous thrombosis and pulmonary emboli...
Asem Mansour,1 Yousef Ismael,2 Mahmoud Abunasser,2 Emad Hammode,2 Rim Turfa,2 Hikmat Abdel-Razeq21De...
PURPOSE: In this cohort study, the rates of pulmonary embolism (PE), myocardial infarction (MI), and...
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary...
PURPOSE: In this cohort study, the rates of pulmonary embolism (PE), myocardial infarction (MI), and...
BACKGROUND: The natural history of unsuspected pulmonary embolism (PE) in patients with cancer has...
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary...
Background Current guidelines suggest treating cancer patients with incidental pulmonary embolism (P...
PURPOSE Pulmonary embolism is incidentally diagnosed in up to 5% of patients with cancer on routine ...
Venous thromboembolism (VTE) is the leading cause of mortality and morbidity in patients with cancer...
Background and objective Malignant tumors are often complicated with pulmonary thromboembolism (PTE)...
BACKGROUND:Pulmonary embolism (PE) is correlated with increased mortality among patients with lung c...
Background: In patients with lung cancer and venous thromboembolism (VTE), the influence of cancer h...
Background: In patients with lung cancer and venous thromboembolism (VTE), the influence of cancer h...
In cancer patients, pulmonary embolism (PE) is the second leading cause of death after the cancer it...
Background and objective Malignant tumors often combined with venous thrombosis and pulmonary emboli...
Asem Mansour,1 Yousef Ismael,2 Mahmoud Abunasser,2 Emad Hammode,2 Rim Turfa,2 Hikmat Abdel-Razeq21De...
PURPOSE: In this cohort study, the rates of pulmonary embolism (PE), myocardial infarction (MI), and...
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary...
PURPOSE: In this cohort study, the rates of pulmonary embolism (PE), myocardial infarction (MI), and...
BACKGROUND: The natural history of unsuspected pulmonary embolism (PE) in patients with cancer has...
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary...
Background Current guidelines suggest treating cancer patients with incidental pulmonary embolism (P...
PURPOSE Pulmonary embolism is incidentally diagnosed in up to 5% of patients with cancer on routine ...
Venous thromboembolism (VTE) is the leading cause of mortality and morbidity in patients with cancer...